Fideuram Asset Management Ireland dac Acquires New Holdings in Stevanato Group S.p.A. $STVN

Fideuram Asset Management Ireland dac acquired a new stake in Stevanato Group S.p.A. (NYSE:STVN) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 52,564 shares of the company’s stock, valued at approximately $1,058,000.

A number of other large investors have also added to or reduced their stakes in the business. First Bank & Trust raised its holdings in Stevanato Group by 5.6% in the 4th quarter. First Bank & Trust now owns 17,109 shares of the company’s stock valued at $344,000 after buying an additional 904 shares during the last quarter. Pathstone Holdings LLC raised its holdings in Stevanato Group by 1.5% in the 3rd quarter. Pathstone Holdings LLC now owns 71,178 shares of the company’s stock valued at $1,833,000 after buying an additional 1,067 shares during the last quarter. Van Berkom & Associates Inc. raised its holdings in Stevanato Group by 50.6% in the 3rd quarter. Van Berkom & Associates Inc. now owns 3,615 shares of the company’s stock valued at $93,000 after buying an additional 1,215 shares during the last quarter. Mariner LLC raised its holdings in Stevanato Group by 6.9% in the 3rd quarter. Mariner LLC now owns 25,447 shares of the company’s stock valued at $655,000 after buying an additional 1,638 shares during the last quarter. Finally, Diversified Trust Co. raised its holdings in Stevanato Group by 12.5% in the 4th quarter. Diversified Trust Co. now owns 16,200 shares of the company’s stock valued at $326,000 after buying an additional 1,800 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts have issued reports on STVN shares. KeyCorp lowered their price target on shares of Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Jefferies Financial Group set a $17.50 price target on shares of Stevanato Group in a report on Tuesday, February 10th. Weiss Ratings lowered shares of Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 11th. Morgan Stanley lowered their price target on shares of Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a report on Friday, March 6th. Finally, Wall Street Zen lowered shares of Stevanato Group from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold”.

Stevanato Group Stock Up 0.2%

Stevanato Group stock opened at €18.70 on Friday. The firm has a market cap of $5.66 billion, a price-to-earnings ratio of 31.70, a PEG ratio of 1.72 and a beta of 0.75. Stevanato Group S.p.A. has a 52-week low of €12.89 and a 52-week high of €28.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63. The firm has a 50 day moving average price of €16.00 and a two-hundred day moving average price of €17.96.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Friday, May 8th. The company reported €0.11 EPS for the quarter, missing the consensus estimate of €0.12 by (€0.01). The company had revenue of €273.57 million for the quarter. Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the business posted $0.10 earnings per share. Equities analysts predict that Stevanato Group S.p.A. will post 0.68 EPS for the current year.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.